相关实验视频
Updated: Sep 11, 2025

09:17
Using Retinal Imaging to Study Dementia
Published on: November 6, 2017
21.8K
视网膜表现及其在阿尔茨海默病的诊断意义
Surabhi D Abhyankar1,2, Karis Little3, Alan Stitt3
1Department of Ophthalmology, Eugene and Marilyn Glick Eye Institute, Indiana University School of Medicine, Indianapolis, IN, USA.
Journal of Alzheimer's disease reports
|August 13, 2025
概括
阿尔茨海默病 (AD) 涉及在症状出现之前可以检测到的视网膜变化. 眼部生物标志物为早期AD检测和理解神经退行提供了一个有希望的途径.
科学领域:
- 神经科学是一个神经科学.
- 眼科医生 眼科 眼科
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,其特点是认知和行为衰退,主要影响65岁以上的人.
- 目前对阿尔茨海默病的治疗方法不会改变疾病的进展,这强调了早期发现和干预策略的必要性.
- 阿尔茨海默病的病理变化在临床症状出现前几年就开始,这给诊断带来了重大挑战.
研究的目的:
- 审查当前对阿尔茨海默病 (AD) 与视网膜变化有关的理解.
- 突出眼部变化的潜力,作为AD诊断和进展的替代标记.
- 探索眼科技术的进步,以识别与AD相关的视网膜生物标志物.
主要方法:
- 审查现有的人类和动物研究,调查早期阿尔茨海默病的视网膜变化.
- 对眼科技术的研究进行分析,以检测眼睛中的AD特异性生物标志物.
- 综合了与AD相关的结构性,血管性,功能性和代谢性视网膜变化的证据.
主要成果:
- 研究表明,在AD的早期阶段,视网膜的结构,血管,功能和代谢变化.
- 用先进的眼科技术,可以在视网膜中识别阿米洛伊德-β和陶蛋白沉积,这是AD的关键标志.
- 视网膜变化与中枢神经系统病理发生并行,这表明视网膜是进入AD过程的窗口.
结论:
- 视网膜表现出与阿尔茨海默病相关的显著变化,即使在早期阶段.
- 眼部生物标志物对早期发现和监测AD有相当大的希望.
- 对视网膜生物标志物的进一步研究可能会彻底改变AD诊断和治疗策略.
相关概念视频
Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668
Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261

